Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Trial Identifier: 6482-043
Sponsor: Merck
Start Date: March 2026
Primary Completion Date: January 2034
Study Completion Date: January 2034
Condition: Genetic Conditions; Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Belgium, Vlaams-Brabant Leuven, Vlaams-Brabant, Belgium, 3000
Canada, QC Montreal, QC, Canada, H3T 1E2
Czech Republic, Olomouc Olomouc, Czech Republic, 77900
Finland, Pirkanmaa Tampere, Pirkanmaa, Finland, 33520
France, Haute-Garonne Toulouse, Haute-Garonne, France, 31059
Hungary, Budapest Budapest, Hungary, 1122
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Israel, N/A Tel Aviv, N/A, Israel, 64239
Japan, Fukuoka Fukuoka, Japan, 812-8582
Korea, Republic of, Seoul Gangnam, Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seodaemun-gu, Seoul, Korea, Republic of, 03722
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Netherlands, Overijssel Zwolle, Overijssel, Netherlands, 8025 AB
Russian Federation, Moskva Moscow, Moskva, Russian Federation, 115478
Russian Federation, Sankt-Peterburg St. Petersburg, Sankt-Peterburg, Russian Federation, 197758
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid Madrid, Spain, 28041
Taiwan, Taipei Taipei, Taiwan, 11217
Ukraine, Dnipropetrovska oblast Dnipropetrovsk, Dnipropetrovska oblast, Ukraine, 49005
Ukraine, Ivano-Frankivska oblast Ivano-Frankivsk, Ivano-Frankivska oblast, Ukraine, 76018
United Kingdom, Manchester Manchester, United Kingdom, M20 4BX
United States, MA Boston, MA, United States, 02215
United States, MI Detroit, MI, United States, 48201
United States, TX San Antonio, TX, United States, 78229